Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
about
The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum.Antineoplastic agents from natural sources: achievements and future directions.A3--a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells.Combinatorial biosynthesis--potential and problems.An integrative expression vector for Actinosynnema pretiosum.Antibiotic producing potentials of three freshwater actinomycetes isolated from the Eastern Cape Province of South Africa.Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.Antibody-DM1 conjugates as cancer therapeutics.Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Molecular biological design of novel antineoplastic therapies.Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates.Tumor-activated prodrugs--a new approach to cancer therapy.N-methylation of the amide bond by methyltransferase asm10 in ansamitocin biosynthesisCancer therapy with radiolabeled and drug/toxin-conjugated antibodies.Antibody-cytotoxic agent conjugates for cancer therapy.Proteomic studies on anti-tumor agent ansamitocin P-3 producer Actinosynnema pretiosum in response to ammonium and isobutanol.In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer.Improved biochemical strategies for targeted delivery of taxoidsPreclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.A general approach to site-specific antibody drug conjugates.Targeting the subtypes of breast cancer: rethinking investigational drugs.Optimising the delivery of tubulin targeting agents through antibody conjugation.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.Endophytic fungus Trichothecium roseum LZ93 antagonizing pathogenic fungi in vitro and its secondary metabolites.When biotech goes bad.Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum.PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability.Disulfide conjugation chemistry: a mixed blessing for therapeutic drug delivery?
P2860
Q24534370-4F602463-BA90-4A20-BCFF-910CAE1D1C81Q30659806-F6F9CCAD-C70B-407F-B98B-D7C1FE0A349AQ30890906-B5B2ACA5-782F-4435-8E65-D38BC5355006Q33231690-1BB10E48-5B51-4CCB-9BA6-2DBA68BA6FB5Q33303641-B6376A21-92B3-4FA6-9512-CEDCC6C62DD9Q34061889-EB095FD3-4813-461C-B18C-14C4FE81C4FDQ34162875-7B78D21C-4F8D-4A91-9ABC-5FF98CC27D61Q34177359-3452875D-CF19-4D3C-8B43-47DF3F972544Q34660299-48C761E8-3327-45A9-8A92-72A34646E060Q35025244-E596904B-45AE-45A5-948E-CD21CC7D6123Q35459059-08AC5B14-3920-446A-88D5-BCDF5632BF51Q35790781-FCEEDD82-B2F2-42B4-B4BE-DE2E03F82641Q35890716-C060A44F-67BB-43C6-9659-034DF20A8CB5Q35964429-6FC55664-4383-4B49-875A-5E9EE0DF015DQ36079969-CB8507E4-AC1E-4CCD-83F3-E579B35D31B5Q36200153-69AA4C51-F624-4845-AA1C-F80E96CF52DEQ36316831-EDF7795D-F584-4C91-A096-4C67988880F2Q36337533-796472E6-204B-4316-A0E3-891BC3F4B6F6Q36407249-911476A9-57DA-4FDF-9B09-6981301BA9BDQ36642502-853ED2E7-74D3-4A3F-BBAB-434555E34F3DQ37138420-5FE1A03A-1299-4F7B-A0A8-F548D16DB0F0Q37402888-6C4FE7CB-F8C6-4373-A27A-F5978CC87705Q37571113-F5710E2C-11D8-4D43-B08D-3C4D0885B194Q37974246-77DE14BF-DB31-42C7-93D5-55D3D3C29DADQ38024991-2E490A71-BE19-4FFD-BB9C-BF76F724DF53Q39645683-444ECB82-81CD-406E-92FE-27ADA9B30691Q42122777-EBC9A7B4-8880-4DCE-85F9-30903303E37BQ42759412-33FDC222-07AD-4B94-A7C6-993BA7DFD5C1Q47801870-B44190D0-0E0A-4AFD-9EE8-8F02671BDD8DQ48202119-590172C3-C1E3-40A2-B3A7-27DE1B377CE6Q50910710-D5EB65C2-0F4D-4B8B-9B24-5165558A2BE1Q51132501-4DB33F90-30D9-4076-B37E-D8B58E2FB9D1Q54611176-F84B040E-1BD7-425E-9565-91BD5654B1B1
P2860
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@ast
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@en
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@nl
type
label
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@ast
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@en
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@nl
prefLabel
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@ast
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@en
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@nl
P2093
P2860
P356
P1476
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids
@en
P2093
Ariniello PD
Blättler WA
Bourret LA
Goldmacher VS
Kedersha NL
Lambert JM
Mattocks KM
P2860
P304
P356
10.1073/PNAS.93.16.8618
P407
P577
1996-08-01T00:00:00Z